Glenmark Eyes Generic Flovent Launch In Coming Months Amid Expected US Resurgence
Indian Firm Awaiting US Audit Of Key Monroe Facility; Ryaltris Strong In Europe
With sales remaining sluggish, on the back of fewer launches, Glenmark’s management nevertheless struck an upbeat tone when discussing the firm’s prospects in the US moving into the company’s 2026 financial year.
